

SESSION 4
MANAGEMENT AND TREATMENT
OF ATRIAL FIBRILLATION AND ARRHYTHMIAS
IN HIGH RISK PATIENTS

M. Anselmino

08.30 *Outline the possible diagnostic flow-chart of management of atrial fibrillation in diabetes. Study cases*

09.30 Discussion

10.00 *Conclusive presentation and state of the art*

10.45 *An update on common arrhythmias*

11.15 Discussion

12.00 *Conclusive presentation and state of the art*

12.30 *Lunch*

Provider Id: 3726 Event RES n° 112219 Edition n. 1
Credits (Italian CME): 19,3

Participants: 40 MD (cardiology, endocrinology, geriatrics, diabetes and metabolic diseases, internal medicine, nephrology, neurology)

PROMOTER

Chaira Medica Association

No-profit organization for the study of endocrine and metabolic disorders

Chieri (Turin) - Italy

chaira.medica@gmail.com

www.chairamedica.it

SCIENTIFIC DIRECTOR

Carlo B. Giorda

Metabolism and Diabetes Unit, ASL TOS - Turin, Italy

giordaca@tin.it

ORGANIZING AGENCY AND ECM PROVIDER

FMR s.r.l.

Via C. Cattaneo, 106 - 41126 MODENA

Tel. 059-350201 - Fax 059-2922506

Cell. 349-0725955

e-mail: mroncaglia@fmrweb.it

FACULTY

M. Anselmino

G. Felace

C.B. Giorda

R. Manti

C. Origlia


M.A. Pellegrini

F. Romeo



6th Post-graduate Updating Course

CURRENT STRATEGIES
TO OPTIMALLY TREAT PATIENTS
WITH DIABETES
AND CO-MORBIDITIES



Turin, Italy
February 19 - 21, 2015

Hotel NH Ambasciatori
C.so Vittorio Emanuele, 104



Post-graduate Updating Course


This is a highly interactive practical course. Appropriate space will be given to workgroups where participants will share knowledge and technical abilities to treat high risk patients. Diagnostic (lab, echo, echodoppler) and therapeutic options will be addressed. Experts will take part in the plenary discussions and give summary and conclusive presentations on the topics.

Target: Cardiologists, Endocrinologists, Geriatrics, Diabetologists, Internists, Nephrologists and Neurologists

Participation includes:

- course attendance and training materials
- certificate of attendance **issued after final examination**
- Continuous Medical Education (ECM) certification for Italian participants

14.00	Update on the course <i>Speaker:</i> C.B. Giorda, Turin (Italy)
14.30	PLENARY SESSION AND OPENING LECTURE How to exploit new drugs and new devices for diabetes treatment and prevention of complications <i>Speaker:</i> C.B. Giorda, Turin (Italy)
<div>SESSION 1 METABOLIC CONTROL AND CARDIOVASCULAR PREVENTION OF COMPLICATIONS IN SPECIAL CONDITIONS C.B. Giorda, R. Manti, F. Romeo</div>	
15.00	<i>Outline the possible diagnostic flow-chart of management of liver disease in diabetes. Study cases</i>
15.30	Discussion
16.15	<i>Conclusive presentation and state of the art</i>
17.00	<i>Outline the possible role of blood glucose monitoring (strips, CGM or flash). Study cases</i>
17.30	Discussion
18.15	<i>Conclusive presentation and state of the art</i>
18.45	End of session

<div>SESSION 2 GERIATRIC SESSION: DIABETES IN THE ELDERLY POPULATION M.A. Pellegrini, G. Felace</div>	
08.45	<i>Outline the possible diagnostic flow-chart of management of elderly patients with diabetes and comorbidities. Study cases</i>
09.15	Discussion
10.00	<i>Conclusive presentation and state of the art</i>
10.45	<i>Outline the possible diagnostic flow-chart of management of CV risk factors of elderly patients with diabetes and comorbidities. Study cases</i>
11.15	Discussion
12.00	<i>Conclusive presentation and state of the art</i>
12.30	<i>Lunch</i>
<div>SESSION 3 HOW TO HANDLE NEW DRUGS FOR METABOLIC DISORDERS G.B. Giorda, C. Origlia, M. Anselmino</div>	
13.30	<i>Use of SLGT2: identify two/three ideal patients</i> <i>Use of GLP-1RA: identify two/three ideal patients</i> <i>Use of new long-acting insulins: identify two/three ideal patients</i> <i>Use of Simvastatina + Fenofibrate</i> <i>Use of Ezetimibe</i>
15.30	<i>Focus on new drugs for hyperuricemia: febuxostat</i>
16.00	Discussion
16.45	<i>Antithrombotic prevention: from study cases to recommendations</i>
17.45	<div></div> <i>Sponsored minilecture</i> <i>Alogliptin and Pioglitazone in combo therapy: pathophysiological and clinical evidence</i>
18.00	End of session